Kazunari Tsuyuguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazunari Tsuyuguchi has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Takehiko Kobayashi
Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan
8 shared publicationsYu Kurahara
Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, Japan; Department of Infectious Diseases, NHO Kinki Chuo Chest Medical Center, Osaka, Japan; Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan
6 shared publications- Shiomi Yoshida
Clinical Research Center, Nho Kinki Chuo Chest Medical Center
4 shared publications Yoshikazu Inoue
Clinical Research Center, National Hospital Organization, Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
4 shared publicationsShiomi Yoshida
Clinical Research Center, National Hospital Organization, Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
3 shared publications- Takehiko Kobayashi
Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Sakai City 591-8555, Osaka, Japan
3 shared publications
Latest Publications
- 11 June 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102441
Changes in skin discoloration according to clofazimine dosage in nontuberculous mycobacterial pulmonary disease
- 11 June 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102441
Changes in skin discoloration according to clofazimine dosage in nontuberculous mycobacterial pulmonary disease
- 4 January 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (8) , 780-784
Efficacy of an oscillating positive expiratory pressure device in patients with Mycobacterium avium complex pulmonary disease
- 4 January 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (8) , 780-784
Efficacy of an oscillating positive expiratory pressure device in patients with Mycobacterium avium complex pulmonary disease
- 1 September 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (1) , 7-11
Utility of a loop-mediated isothermal amplification detection kit to diagnose chronic pulmonary aspergillosis
- 1 September 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (1) , 7-11
Utility of a loop-mediated isothermal amplification detection kit to diagnose chronic pulmonary aspergillosis
- Open Access
- 27 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4940
COVID-19 in Patients with Pre-Existing Interstitial Lung Disease: Potential Value of a Steroid-Based Treatment Strategy
The prognosis of patients with coronavirus disease 2019 (COVID-19) and pre-existing interstitial lung disease (preILD) is poor, and no effective treatment strategy has been determined. The aim of this study was to assess the effectiveness of a steroid-based treatment strategy for patients with COVID-19 and preILD. We retrospectively reviewed the medical records of 610 consecutive patients with COVID-19 treated at our institution between 1 March 2020 and 30 October 2021 and identified 7 patients with preILD, all of whom were treated with corticosteroids and remdesivir. All the patients were men with a median age of 63 years. Three of four patients with severe disease required invasive positive-pressure ventilation (n = 2) or nasal high-flow therapy (n = 1). All three patients could be weaned from respiratory support; however, one died in hospital. The remaining patient with severe COVID-19 had a do-not-resuscitate order in place and died while hospitalized. All three patients with moderate COVID-19 were discharged. The 30-day mortality was 0%, and the mortality rate during the entire observation period was 28.5%. The prognosis of our patients with COVID-19 and preILD has been better than in previous reports. Our management strategy using corticosteroids may have improved these patients’ prognosis.
- 27 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4940
Open AccessCOVID-19 in Patients with Pre-Existing Interstitial Lung Disease: Potential Value of a Steroid-Based Treatment Strategy
The prognosis of patients with coronavirus disease 2019 (COVID-19) and pre-existing interstitial lung disease (preILD) is poor, and no effective treatment strategy has been determined. The aim of this study was to assess the effectiveness of a steroid-based treatment strategy for patients with COVID-19 and preILD. We retrospectively reviewed the medical records of 610 consecutive patients with COVID-19 treated at our institution between 1 March 2020 and 30 October 2021 and identified 7 patients with preILD, all of whom were treated with corticosteroids and remdesivir. All the patients were men with a median age of 63 years. Three of four patients with severe disease required invasive positive-pressure ventilation (n = 2) or nasal high-flow therapy (n = 1). All three patients could be weaned from respiratory support; however, one died in hospital. The remaining patient with severe COVID-19 had a do-not-resuscitate order in place and died while hospitalized. All three patients with moderate COVID-19 were discharged. The 30-day mortality was 0%, and the mortality rate during the entire observation period was 28.5%. The prognosis of our patients with COVID-19 and preILD has been better than in previous reports. Our management strategy using corticosteroids may have improved these patients’ prognosis.
- 22 April 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (8) , 812-815
Cases of severe Mycobacterium avium lung disease occurred in a married couple caused by identical strain
- 22 April 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (8) , 812-815
Cases of severe Mycobacterium avium lung disease occurred in a married couple caused by identical strain
- Open Access
- 15 April 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (8) , 1237-1241
Mycobacterium avium Pleurisy with Bronchopleural Fistula Resulting in Rapidly Progressive Respiratory Failure Diagnosed by Transbronchial Autopsy
Nontuberculous mycobacterial lung disease usually manifests as a chronic pulmonary infection. We herein report a fatal case of Mycobacterium avium pleurisy in a man with a refractory bronchopleural fistula that led to rapidly progressive pneumonia. A post-mortem transbronchial biopsy was performed. Histopathology revealed an acute lung injury pattern and epithelioid granulomas. Variable number tandem repeat analyses and drug susceptibility testing revealed Mycobacterium avium had acquired macrolide resistance during chemotherapy with rifampicin, ethambutol, and clarithromycin. Clinicians should be aware that Mycobacterium avium pleurisy with bronchopleural fistula can lead to fatal pneumonia, especially in patients with persistently positive cultures despite multidrug treatment.
- 15 April 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (8) , 1237-1241
Open AccessMycobacterium avium Pleurisy with Bronchopleural Fistula Resulting in Rapidly Progressive Respiratory Failure Diagnosed by Transbronchial Autopsy
Nontuberculous mycobacterial lung disease usually manifests as a chronic pulmonary infection. We herein report a fatal case of Mycobacterium avium pleurisy in a man with a refractory bronchopleural fistula that led to rapidly progressive pneumonia. A post-mortem transbronchial biopsy was performed. Histopathology revealed an acute lung injury pattern and epithelioid granulomas. Variable number tandem repeat analyses and drug susceptibility testing revealed Mycobacterium avium had acquired macrolide resistance during chemotherapy with rifampicin, ethambutol, and clarithromycin. Clinicians should be aware that Mycobacterium avium pleurisy with bronchopleural fistula can lead to fatal pneumonia, especially in patients with persistently positive cultures despite multidrug treatment.
- 16 January 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (4) , 558-562
The feasibility of rifampicin Re-administration in patients with tuberculosis and Clostridioides difficile infection
- 16 January 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (4) , 558-562
The feasibility of rifampicin Re-administration in patients with tuberculosis and Clostridioides difficile infection
- 10 September 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 810-818
Clinical characteristics of COVID-19 in Osaka, Japan: Comparison of the first–third waves with the fourth wave
- 10 September 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 810-818
Clinical characteristics of COVID-19 in Osaka, Japan: Comparison of the first–third waves with the fourth wave
- 1 July 2020
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 26 (7) , 676-680
Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease
- 1 July 2020
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 26 (7) , 676-680
Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease